Spotlight on atezolizumab and its potential as an oncology agent

Expert Rev Anticancer Ther. 2018 Aug;18(8):719-722. doi: 10.1080/14737140.2018.1483241. Epub 2018 Jun 7.

Authors

Jason M Redman¹, Ravi A Madan²

Affiliations

¹ a Medical Oncology Service Branch , National Cancer Institute, National Institutes of Health , Bethesda , MD , USA.
² b Genitourinary Malignancies Branch , National Cancer Institute, National Institutes of Health , Bethesda , MD , USA.

PMID: 29877103
DOI: 10.1080/14737140.2018.1483241

No abstract available

Keywords: Lung cancer; anti-PD-L1; checkpoint inhibitor; combination immunotherapy; immunotherapy; urothelial cancer.

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal / pharmacology
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy
Carcinoma, Transitional Cell / drug therapy
Humans
Lung Neoplasms / drug therapy
Urinary Bladder Neoplasms / drug therapy

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
atezolizumab